Seeking Alpha

Accretive Health (AH +1%) is still poised to generate strong growth despite the loss of its...

Accretive Health (AH +1%) is still poised to generate strong growth despite the loss of its Fairview Health Systems revenue cycle contract, says JPMorgan. The firm says the underlying franchise is attractive, noting the settlement of Minnesota's lawsuit against the company could provide a positive catalyst for the stock over the next few months.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs